Biopharma and dating apps may seem like unlikely comparisons, but both face a similar challenge—matching the right people with the right opportunity. Dating platforms have mastered the art of engagement, using algorithms, user experience design, and behavioural insights to create connections that last. Meanwhile, clinical trials still struggle with outdated recruitment methods, low engagement, and high dropout rates. If biopharma patient recruitment adopted some of the strategies dating apps use to attract and retain users, clinical trials could see a dramatic shift in participation and success rates.
Dating apps thrive on precision. They use data-driven matching algorithms to connect individuals based on compatibility, interests, and behaviour. The process is seamless, personalised, and designed to keep users engaged. Biopharma, on the other hand, still relies on broad outreach efforts, hoping that the right patients will somehow find their way into trials.
The reality is that clinical trials need a smarter approach. Biopharma patient recruitment can benefit from AI-driven patient matching, similar to how dating apps refine searches based on preferences. Personalised recruitment strategies, driven by data on patient demographics, medical history, and trial eligibility, can replace the inefficient mass recruitment methods that lead to high screen failure rates.
Another lesson lies in user experience. Dating apps make the process simple—swipe, match, chat. Clinical trial platforms are often cumbersome, filled with dense medical terminology and unclear participation steps. Streamlining trial portals and simplifying sign-up processes can create a more patient-friendly experience, increasing the likelihood of retention.
Trial platforms could also benefit from recommendation engines similar to those used in dating apps. Instead of making patients sift through complex lists of available trials, intelligent algorithms could suggest relevant studies based on a patient’s profile, ensuring a more tailored experience and reducing the likelihood of mismatched enrollments.
In dating, engagement isn’t just about making a match; it’s about keeping interest alive. A well-designed dating app knows how to bring users back, whether through push notifications, curated recommendations, or interactive content. Clinical trials, however, often lose engagement after the initial sign-up phase, with patients dropping out due to lack of communication, long wait times, or unclear expectations.
This is where clinical trial engagement needs a rethink. Regular updates, personalised reminders, and ongoing patient support can make the process feel less like a one-time transaction and more like an ongoing relationship. Just as dating apps keep users engaged with relevant content, biopharma can maintain patient interest through educational resources, trial updates, and direct interaction with researchers.
Patients also need reassurance that their participation matters. Just as dating apps offer validation through matches and messages, clinical trials can improve retention by showing patients how their involvement contributes to medical advancements. Transparency around trial progress, patient impact stories, and real-time feedback loops can turn passive participants into active trial advocates.
Providing incentives for clinical trial engagement could further enhance retention. While dating apps use gamification elements like badges and streaks to encourage activity, clinical trials could implement reward-based engagement systems, such as patient recognition programs, milestone updates, or even financial incentives for completing follow-up visits.
Signing up for a clinical trial can feel like a long-term commitment with unknown risks. The same could be said for dating. Yet dating apps have made it easy to explore connections without feeling locked in. They allow users to browse options, engage at their own pace, and opt out when necessary. Clinical trials, by contrast, often require an immediate commitment without fully addressing patient concerns or hesitations.
Creating a low-pressure entry point could make a difference. Pre-trial engagement strategies—such as virtual consultations, interactive Q&A sessions, and trial previews—could help patients make informed decisions without feeling rushed. Giving potential participants opportunities to learn more about the trial before officially enrolling could significantly improve recruitment rates.
Transparency is another factor. Dating apps set clear expectations by showing user profiles, outlining compatibility scores, and providing insights into potential matches. Clinical trials could adopt a similar approach by offering clear, digestible information about study goals, risks, time commitments, and potential outcomes. This kind of openness builds trust and reduces uncertainty.
Additionally, offering a phased entry into trials could help patients ease into participation. Just as dating apps allow users to communicate before meeting in person, clinical trials could introduce pre-trial education sessions or preliminary health assessments to help patients feel more comfortable before full enrollment.
Dating apps succeed because they make users feel like the experience is tailored just for them. Every match, message, and notification is based on user data, ensuring relevance and engagement. Clinical trials, on the other hand, often fail to create this sense of personalisation. Generic recruitment emails, rigid eligibility criteria, and one-size-fits-all outreach efforts fail to connect with patients on an individual level.
A shift toward personalised recruitment could change this. Leveraging patient data to create customised trial recommendations, offering flexible participation options, and providing individualised support can make clinical research more approachable. Patients are more likely to enrol and stay engaged when they feel the trial is designed with their specific needs in mind.
Technology can play a crucial role here. Mobile apps, AI-driven chatbots, and digital health tracking tools can make trial participation feel seamless and integrated into daily life. Patients should receive reminders, progress updates, and personalised check-ins that reinforce their importance in the study.
Biopharma could also explore interactive content strategies similar to dating apps, using patient-friendly quizzes, symptom trackers, or chat-based eligibility assessments to make the recruitment process feel less clinical and more engaging.
The success of dating apps proves that engagement isn’t just about offering opportunities—it’s about making those opportunities easy, appealing, and rewarding. Biopharma must take the same approach. Patient recruitment should not be a last-minute scramble but a well-thought-out strategy that prioritises user experience, personalisation, and ongoing communication. By applying these principles, clinical trials can move away from outdated recruitment models and towards a system that values the patient journey as much as the research itself.
Keith Berelowitz is the Founder of trialport, a company redefining patient engagement and retention in clinical trials using living experience, proven methods, and AI.